TransMedics (TMDX) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.08 per share a year ago.

Besides Wall Street's top -and-bottom-line estimates for TransMedics (TMDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during...

In the latest trading session, TransMedics (TMDX) closed at $88.88, marking a -1.9% move from the previous day.

TransMedics (TMDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In the closing of the recent trading day, TransMedics (TMDX) stood at $84.74, denoting a +0.69% change from the preceding trading day.

TransMedics (TMDX) reachead $91.82 at the closing of the latest trading day, reflecting no change compared to its last close.

FY2023: TransMedics' revenues up 159%, profitability improves, breakeven could be on the horizon. Potential 2x top-line growth medium term in the U.S. alone. TransMedics' Organ Care System (OCS) co...

TransMedics Group is transforming the organ transplant landscape with its expansive transplant solutions. The company has a proven technology, FDA approved, making it a rare early commercial-stage ...

ANDOVER, Mass. , Feb. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with e...

TransMedics Group, Inc. (TMDX) Q4 2023 Earnings Call Transcript

TransMedics has a dominant market position in the organ transplant market due to its revolutionary Organ Care System product, which helps organs survive longer, enabling significantly greater reach...

TransMedics (TMDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

TransMedics Group, Inc. revolutionizes organ transplants with its patented OCS technology, fueling significant growth and industry-leading position. Strategic aviation expansion and advanced OCS de...

Shares of TransMedics surged when it reported strong Q3 results and raised full-year guidance. The company's Organ Care System has a strong value proposition over cold storage solutions, and this h...

TransMedics Group's transplant organ retrieval and delivery business is accelerating now that it doesn't have to rely on third parties for charter flights. Verve Therapeutics and its partnership wi...